A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Cannabidiol (Primary) ; Vigabatrin
- Indications Infantile spasms
- Focus Registrational; Therapeutic Use
- Sponsors Benuvia Therapeutics; INSYS Therapeutics, Inc; Radius
- 11 May 2023 Status changed from active, no longer recruiting to discontinued.
- 16 May 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2018 According to an INSYS Therapeutics, Inc. media release, enrollment in the study of infantile spasms has occurred at a slower pace than anticipated, and the company will provide an update once it has better visibility into enrollment.